The association between<unk>  concentration and cardiovascular outcomes, especially in statin treated high-risk patients with residual cardiovascular risks, has triggered a large interest in the evaluation of<unk>  lowering drugs. <unk>  is one of the most complicated and heterogeneous among the different lipoproteins; in fact,<unk>  subfractions vary largely in function, structure, size, cholesterol and triglyceride contents.  The widely used method of measurement of<unk>  is based on the chemical measurement of<unk> -cholesterol <unk> -C); however, recent evidence suggests that<unk> -C might not be the best method to measure the functionality of<unk>  and assess its relationship with cardiovascular outcomes among statin treated patients. Recent studies postulate that<unk> -particles <unk> -p) might be a better measure for<unk> 's effect on residual cardiovascular risks.
HDL laboratory test
Triglyceride biochemistry
Thrombophilia screening
Hemochromatosis screening
High density lipoprotein screening
Hypoglycemia screening
Metabolic syndrome screening
Diabetic foot screening